Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5Phase 1/2 5Phase 1 2Phase NA 1Phase 2/3 1

Status

Completed 3Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 2Gynecologic 1

Conditions

Multiple Myeloma 20Leukemia, Myeloid, Acute 8Recurrence 7Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Thymoma 2Ovarian Neoplasms 2Carcinoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Richter's Transformation 1Rhabdoid Tumor 1Prostatic Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Melanoma 1MDS 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × selinexor × Clear all
NCT05530421 2026-02-23

SELVEDge

University of Miami

Phase 2 Recruiting
33 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University

Phase 2 Recruiting
40 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT06212596 2024-01-19

MUKtwelve

University of Leeds

Phase 2 Completed
66 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05951855 2023-07-19

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

The First Affiliated Hospital of Soochow University

Phase 2 Unknown
42 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03944057 2023-06-15

MARCH

Antengene Corporation

Phase 2 Completed
82 enrolled 9 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT05170789 2022-05-04

ESdRRMM

Tulane University

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT02249091 2021-08-25

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

GSO Global Clinical Research BV

Phase 2 Completed
42 enrolled 16 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡